US Stock MarketDetailed Quotes

CYBN Cybin

Watchlist
  • 7.2100
  • -0.1700-2.30%
Close Mar 25 16:00 ET
  • 7.2100
  • 0.00000.00%
Post 20:01 ET
151.60MMarket Cap-2.08P/E (TTM)

About Cybin Company

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Company Profile

SymbolCYBN
Company NameCybin
Listing DateAug 5, 2021
Founded2016
CEOMr. Douglas Drysdale
MarketAMEX
Employees50
Fiscal Year Ends03-31
Address100 King Street West,Suite 5600
CityToronto
ProvinceOntario
CountryCanada
Zip CodeM5X 1C9
Phone1-908-764-8385

Company Executives

  • Name
  • Position
  • Salary
  • Douglas Drysdale
  • Chief Executive Officer
  • 2.09M
  • Alex Nivorozhkin
  • Chief Scientific Officer
  • --
  • Aaron Bartlone
  • Chief Operation Officer
  • 1.03M
  • Paul Glavine
  • Director and Chief Growth Officer
  • 3.36M
  • George Tziras
  • Director and Chief Business Officer
  • 310.55K
  • Gabriel Fahel
  • Chief Legal Officer and Corporate Secretary
  • --
  • Greg Cavers
  • Chief Financial Officer
  • 880.42K
  • Eric So
  • Director and President
  • 3.36M
  • Grant Froese
  • Independent Director
  • 289.80K
  • Mark Lawson
  • Independent Director
  • 291.56K
  • Dr. Eric Hoskins
  • Independent Director
  • 289.80K
  • Theresa Firestone
  • Lead Independent Director
  • 304.80K

Market Insights

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More